SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 210

Change

-3.75 (-1.75)%

Market Cap

N/A

Volume

646.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-1.87 (-4.25%)

USD 96.80B
EUNL:XETRA iShares Core MSCI World UCITS ..

-4.83 (-4.92%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-1.19 (-5.21%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.49 (-3.83%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.28 (-5.29%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.93 (-4.19%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.70 (-5.54%)

USD 23.43B
PPFB:XETRA iShares Physical Gold ETC EUR

-1.37 (-2.45%)

USD 19.49B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.34 (-3.39%)

USD 12.83B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.03 (-0.02%)

USD 12.26B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.38% 63% D 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.38% 65% D 60% D-
Trailing 12 Months  
Capital Gain -2.01% 18% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.01% 20% F 25% F
Trailing 5 Years  
Capital Gain 41.80% 39% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.80% 39% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 9.40% 61% D- 61% D-
Dividend Return 9.40% 60% D- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.87% 71% C- 77% C+
Risk Adjusted Return 119.44% 96% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike